Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.

CONCLUSION: A patient with HCC was successfully treated with pembrolizumab after experiencing adverse effects with nivolumab. PMID: 31612928 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31612928?dopt=Abstract

Source: American Journal of Health-System Pharmacy : AJHP - October 14, 2019 Category: Drugs & Pharmacology Authors: Choi B, McBride A, Scott AJ Tags: Am J Health Syst Pharm Source Type: research